Machine learning for Ebola drug discovery
What is it about?
Our previously published Ebola models from 2015 were rebuilt with Assay Central, tested with external datasets and used to select additional compounds for testing. This extends our earlier work in that this time we tested many more compounds and also looked at different .
Why is it important?
We used a couple of papers by others to provide external test sets and demonstrate that the machine learning models would have identified many of these compounds as active. Several further in vitro active compounds were identified e.g. Arterolane and Lucanthone.
The following have contributed to this page: Dr Sean Ekins